Recombinant DNA technology has allowed the production of antigenic polypeptides of pathogen in bacteria or yeast. Vaccines produced using this approach in bacteria or yeast, allow large scale production and hence greater availability for immunization, $e.g.,$ hepatitis-B vaccine produced from yeast